CluenexHalozyme Therapeutics HALO
Halozyme Therapeutics scores excellent on business quality (7.9 of 10). Here is why, in plain words, and what our sealed record shows.
Why it matters
- What Halozyme Therapeutics does
Halozyme Therapeutics licenses drug delivery technology, primarily its ENHANZE platform, enabling subcutaneous administration of biologic therapies traditionally given intravenously. Partner pharmaceutical companies pay royalties and milestones on commercialized drugs. The company is scaling its partner pipeline while expanding into new auto-injector formats to sustain growth across global markets.
- What it does best
Halozyme dominates subcutaneous drug delivery through its proprietary ENHANZE enzyme technology, yielding an operating margin of 35.6% that ranks in the top decile of its sector. This edge relies on entrenched partner formulations and long-term biologic patent exclusivity.
- The main risk
Heavy revenue reliance on partner-driven biologic drugs creates exposure to clinical setbacks or patent expirations outside Halozyme's direct control, threatening high-margin royalty streams.
Quality, check by check
Scored against its own industry, from company filings.
Operating margin rests at 35.6% with a net margin of 24.9%, expanding as high-margin royalty revenues scale efficiently without proportional operating cost increases.
A regulatory and IP-backed moat locks in major pharmaceutical partners through multi-year drug delivery agreements, supporting a top-decile 92nd percentile operating margin rank.
Revenue grew 37.6% over the latest period, pacing in the top decile of its sector at 96th percentile and accelerating above its historical multi-year expansion rate.
Net debt sits at $2.0B alongside interest coverage of 29.1x, making debt servicing manageable while free cash flow hits $519M, signaling a stable balance sheet.
Insiders
Executives and directors, from SEC Form 4 filings we read ourselves. Open market trades only; grants, option exercises and pre-planned sales left out.
No open market buys or unplanned sales by executives or directors.
Our sealed record on HALO
Verdicts appear here 30 days after we publish them; members see today's. Each one is in the nightly ledger, fingerprinted the night it was made.
The first sealed verdicts appear here on Oct 11, 2026.
Questions
Halozyme Therapeutics scores excellent on the Cluenex quality check (7.9 of 10), measured against its own industry. Profitability is strong, moat strong, growth fast and financial health fair.
In the last 90 days of SEC Form 4 filings: No open market buys or unplanned sales by executives or directors.
Nov 2, 2026.
See HALO today
- Today's verdict on HALO, and why
- Fair value with cautious, base and optimistic cases
- The exact price that would change the verdict
- Which stocks each signal names, the night it fires
Cite this page: Cluenex, “Halozyme Therapeutics (HALO)”, https://cluenex.com/stocks/halo/, data as of Oct 10, 2026.